|
1
|
Gatto M and Alvaro D: New insights on
cholangiocarcinoma. World J Gastrointest Oncol. 2:136–145. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jarnagin WR, Fong Y, DeMatteo RP, Gonen M,
Burke EC, Bodniewicz BS J, Youssef BA M, Klimstra D and Blumgart
LH: Staging, resectability, and outcome in 225 patients with hilar
cholangiocarcinoma. Ann Surg. 234:507–519. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rizvi S, Khan SA, Hallemeier CL, Kelley RK
and Gores GJ: Cholangiocarcinoma-evolving concepts and therapeutic
strategies. Nat Rev Clin Oncol. 15:95–111. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Valle J, Wasan H, Palmer DH, Cunningham D,
Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira
SP, et al: Cisplatin plus gemcitabine versus gemcitabine for
biliary tract cancer. N Engl J Med. 362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tebay LE, Robertson H, Durant ST, Vitale
SR, Penning TM, Dinkova-Kostova AT and Hayes JD: Mechanisms of
activation of the transcription factor Nrf2 by redox stressors,
nutrient cues, and energy status and the pathways through which it
attenuates degenerative disease. Free Radic Biol Med. 88:108–146.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Orskov C, Rabenhøj L, Wettergren A, Kofod
H and Holst JJ: Tissue and plasma concentrations of amidated and
glycine-extended glucagon-like peptide I in humans. Diabetes.
43:535–539. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee YS and Jun HS: Anti-diabetic actions
of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism.
63:9–19. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Karaca M, Magnan C and Kargar C:
Functional pancreatic beta-cell mass: Involvement in type 2
diabetes and therapeutic intervention. Diabetes Metab. 35:77–84.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Drucker DJ: The biology of incretin
hormones. Cell Metab. 3:153–165. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tremblay AJ, Lamarche B, Deacon CF,
Weisnagel SJ and Couture P: Effects of sitagliptin therapy on
markers of low-grade inflammation and cell adhesion molecules in
patients with type 2 diabetes. Metabolism. 63:1141–1148. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Drucker DJ, Habener JF and Holst JJ:
Discovery, characterization, and clinical development of the
glucagon-like peptides. J Clin Invest. 127:4217–4227. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Elashoff M, Matveyenko AV, Gier B,
Elashoff R and Butler PC: Pancreatitis, pancreatic, and thyroid
cancer with glucagon-like peptide-1-based therapies.
Gastroenterology. 141:150–156. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Koehler JA, Baggio LL, Yusta B, Longuet C,
Rowland KJ, Cao X, Holland D, Brubaker PL and Drucker DJ: GLP-1R
agonists promote normal and neoplastic intestinal growth through
mechanisms requiring Fgf7. Cell Metab. 21:379–391. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Spranger J, Gundert-Remy U and
Stammschulte T: GLP-1-based therapies: The dilemma of uncertainty.
Gastroenterology. 141:20–23. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen BD, Zhao WC, Dong JD and Sima H:
Expression of GLP-1R protein and its clinical role in intrahepatic
cholangiocarcinoma tissues. Mol Biol Rep. 41:4313–4320. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen BD, Zhao WC, Jia QA, Zhou WY, Bu Y,
Wang ZZ, Wang F, Wu WJ and Wang Q: Effect of the GLP-1 analog
exendin-4 and oxaliplatin on intrahepatic cholangiocarcinoma cell
line and mouse model. Int J Mol Sci. 14:24293–24304. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Calnan DR and Brunet A: The FoxO code.
Oncogene. 27:2276–2288. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hedrick SM: The cunning little vixen: Foxo
and the cycle of life and death. Nat Immunol. 10:1057–1063. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lam EW, Brosens JJ, Gomes AR and Koo CY:
Forkhead box proteins: Tuning forks for transcriptional harmony.
Nat Rev Cancer. 13:482–495. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Deng Y, Wang F, Hughes T and Yu J: FOXOs
in cancer immunity: Knowns and unknowns. Semin Cancer Biol.
50:53–64. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee J, Hong SW, Chae SW, Kim DH, Choi JH,
Bae JC, Park SE, Rhee EJ, Park CY, Oh KW, et al: Exendin-4 improves
steatohepatitis by increasing Sirt1 expression in high-fat
diet-induced obese C57BL/6J mice. PLoS One. 7:e313942012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jackson JG, Pant V, Li Q, Chang LL,
Quintás-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, et
al: p53-mediated senescence impairs the apoptotic response to
chemotherapy and clinical outcome in breast cancer. Cancer Cell.
21:793–806. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Choi W, Porten S, Kim S, Willis D, Plimack
ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, et al:
Identification of distinct basal and luminal subtypes of
muscle-invasive bladder cancer with different sensitivities to
frontline chemotherapy. Cancer Cell. 25:152–165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ihle NT, Byers LA, Kim ES, Saintigny P,
Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, et al:
Effect of KRAS oncogene substitutions on protein behavior:
Implications for signaling and clinical outcome. J Natl Cancer
Inst. 104:228–239. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shibue T and Weinberg RA: EMT, CSCs, and
drug resistance: The mechanistic link and clinical implications.
Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xia L, Huang W, Tian D, Zhu H, Qi X, Chen
Z, Zhang Y, Hu H, Fan D, Nie Y and Wu K: Overexpression of forkhead
box C1 promotes tumor metastasis and indicates poor prognosis in
hepatocellular carcinoma. Hepatology. 57:610–624. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li W, Zhang Z, Liu X, Cheng X, Zhang Y,
Han X, Zhang Y, Liu S, Yang J, Xu B, et al: The FOXN3-NEAT1-SIN3A
repressor complex promotes progression of hormonally responsive
breast cancer. J Clin Invest. 127:3421–3440. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim T, Ha HI, Kim N, Yi O, Lee SH and Choi
Y: Adrm1 interacts with Atp6v0d2 and regulates osteoclast
differentiation. Biochem Biophys Res Commun. 390:585–590. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhou Z, Zhang L, Xie B, Wang X, Yang X,
Ding N, Zhang J, Liu Q, Tan G, Feng D and Sun LQ: FOXC2 promotes
chemoresistance in nasopharyngeal carcinomas via induction of
epithelial mesenchymal transition. Cancer Lett. 363:137–145. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chiu WT, Huang YF, Tsai HY, Chen CC, Chang
CH, Huang SC, Hsu KF and Chou CY: FOXM1 confers to
epithelial-mesenchymal transition, stemness and chemoresistance in
epithelial ovarian carcinoma cells. Oncotarget. 6:2349–2365. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Saxena M, Stephens MA, Pathak H and
Rangarajan A: Transcription factors that mediate
epithelial-mesenchymal transition lead to multidrug resistance by
upregulating ABC transporters. Cell Death Dis. 2:e1792011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cai J, Tian AX, Wang QS, Kong PZ, Du X, Li
XQ and Feng YM: FOXF2 suppresses the FOXC2-mediated
epithelial-mesenchymal transition and multidrug resistance of
basal-like breast cancer. Cancer Lett. 367:129–137. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xing YQ, Li A, Yang Y, Li XX, Zhang LN and
Guo HC: The regulation of FOXO1 and its role in disease
progression. Life Sci. 193:124–131. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dong T, Zhang Y, Chen Y, Liu P, An T,
Zhang J, Yang H, Zhu W and Yang X: FOXO1 inhibits the invasion and
metastasis of hepatocellular carcinoma by reversing ZEB2-induced
epithelial-mesenchymal transition. Oncotarget. 8:1703–1713.
2017.PubMed/NCBI
|
|
37
|
Zhang X, Gan L, Pan H, Guo S, He X, Olson
ST, Mesecar A, Adam S and Unterman TG: Phosphorylation of serine
256 suppresses transactivation by FKHR (FOXO1) by multiple
mechanisms. Direct and indirect effects on nuclear/cytoplasmic
shuttling and DNA binding. J Biol Chem. 277:45276–45284. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang H, Regan KM, Wang F, Wang D, Smith
DI, van Deursen JM and Tindall DJ: Skp2 inhibits FOXO1 in tumor
suppression through ubiquitin-mediated degradation. Proc Natl Acad
Sci USA. 102:1649–1654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rena G, Prescott AR, Guo S, Cohen P and
Unterman TG: Roles of the forkhead in rhabdomyosarcoma (FKHR)
phosphorylation sites in regulating 14-3-3 binding, transactivation
and nuclear targetting. Biochem J. 354:605–612. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu J, Yin F, Xiao H, Guo L and Gao X:
Glucagon-like peptide 1 receptor plays an essential role in
geniposide attenuating lipotoxicity-induced β-cell apoptosis.
Toxicol In Vitro. 26:1093–1097. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang Y, Xia Z, Liu J and Yin F: Cell
signaling mechanisms by which geniposide regulates
insulin-degrading enzyme expression in primary cortical neurons.
CNS Neurol Disord Drug Targets. 14:370–377. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wewer Albrechtsen NJ, Albrechtsen R,
Bremholm L, Svendsen B, Kuhre RE, Poulsen SS, Christiansen CB,
Jensen EP, Janus C, Hilsted L, et al: Glucagon-like peptide 1
receptor signaling in acinar cells causes growth-dependent release
of pancreatic enzymes. Cell Rep. 17:2845–2856. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Roy SK, Chen Q, Fu J, Shankar S and
Srivastava RK: Resveratrol inhibits growth of orthotopic pancreatic
tumors through activation of FOXO transcription factors. PLoS One.
6:e251662011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Forst T, Weber MM and Pfutzner A:
Cardiovascular benefits of GLP-1-based herapies in patients with
diabetes mellitus type 2: Effects on endothelial and vascular
dysfunction beyond glycemic control. Exp Diabetes Res.
2012:6354722012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Buteau J, Roduit R, Susini S and Prentki
M: Glucagon-like peptide-1 promotes DNA synthesis, activates
phosphatidylinositol 3-kinase and increases transcription factor
pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding
activity in beta (INS-1)-cells. Diabetologia. 42:856–864. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kanda R, Hiraike H, Wada-Hiraike O,
Ichinose T, Nagasaka K, Sasajima Y, Ryo E, Fujii T, Osuga Y and
Ayabe T: Expression of the glucagon-like peptide-1 receptor and its
role in regulating autophagy in endometrial cancer. BMC Cancer.
18:6572018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhao H, Wang L, Wei R, Xiu D, Tao M, Ke J,
Liu Y, Yang J and Hong T: Activation of glucagon-like peptide-1
receptor inhibits tumourigenicity and metastasis of human
pancreatic cancer cells via PI3K/Akt pathway. Diabetes Obes Metab.
16:850–860. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gao Q, Yu GY, Shi JY, Li LH, Zhang WJ,
Wang ZC, Yang LX, Duan M, Zhao H, Wang XY, et al: Neddylation
pathway is up-regulated in human intrahepatic cholangiocarcinoma
and serves as a potential therapeutic target. Oncotarget.
5:7820–7832. 2014. View Article : Google Scholar : PubMed/NCBI
|
